Quantcast

Latest Selexis SA Stories

2015-01-22 23:07:03

Selexis SA Is the First Biotechnology Company to Deliver Manufacturing-Ready Research Cell Banks with a Fully Sequenced Genome and Transcriptome Geneva, Switzerland

2015-01-08 23:06:47

Selexis SA announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform™ has been approved for market. Geneva, Switzerland

2014-12-09 23:03:35

Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment

2014-10-14 23:09:20

Selexis has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development for Europe. Geneva,

2014-09-25 12:30:28

ReportsnReports.com adds "Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity

2014-07-30 23:05:41

Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in mammalian cell lines Geneva, Switzerland

2014-06-05 23:09:14

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing

2014-04-23 23:04:53

Company CSO to Present Data on the Selexis SURE CHO-Mplus™ Libraries Geneva, Switzerland (PRWEB) April 23, 2014 Selexis SA, a serial innovation company


Word of the Day
postliminy
  • In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
  • In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.
The word 'postliminy' comes from a Latin word meaning 'threshold'.